NCT07056439尚未招募1 期
A Phase I/II Clinical Study to Evaluate the Safety, Pharmacokinetics, Radiation Dosimetry and Preliminary Diagnostic Efficacy of HRS-1738 in PET/CT Imaging of Patients With Prostate Cancer
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Adverse events (AEs)
研究概览
简要总结
This study aims to evaluate the safety and pharmacokinetics of HRS-1738 injection in adult patients with prostate cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Be able to understand and abide by the procedures and requirements of this study and voluntarily sign the informed consent form.
- •Male, aged ≥18 years old.
- •ECOG (Eastern Oncology Collaboration) Physical Condition score: 0 or
- •Prostate adenocarcinoma confirmed by histopathology.
- •The distance between enrollment and the most recent surgical treatment should be at least 12 weeks. If the patient has recovered from the surgery before enrollment and meets other enrollment criteria, it can be relaxed to 8 weeks as determined by the investigator.
- •The functions of the major organs should meet the requirements.
- •For male subjects, they need to agree to take effective contraceptive measures with their partners within one week after the last administration of the investigational drug from the date of signing the informed consent form, and have no plans for fertility and do not donate sperm.
排除标准
- •Combined with the following diseases:
- •. Severe urinary incontinence, hydronephrosis, severe urinary dysfunction, etc. Note: Subjects with bladder outflow tract obstruction or urinary incontinence who can be controlled through the existing best standard treatment (including urinary pads, drainage, etc.) are eligible to participate in the study.
- •. Concurrent active infection or unexplained fever >38.5℃ for more than 1 hour during the screening period and before administration.
- •. Combined with severe or poorly controlled systemic diseases, including but not limited to poorly controlled diabetes, congestive heart failure, unstable angina pectoris, myocardial infarction that occurred within 6 months before administration, refractory hypertension, acute kidney injury, stroke, and severe liver injury.
- •. Combined with active hepatitis B (HBV-DNA testing is required for HBsAg positive patients, and HBV DNA≥2000 IU/mL or 104 copies/mL), active hepatitis C (HCV-Ab positive and higher than the detection limit of the analytical method).
- •. Those who are known to have tested positive for acquired immunodeficiency syndrome (AIDS) or human immunodeficiency virus (HIV).
- •. Active syphilis infected individuals.
- •According to the NCI-CTCAE v5.0 classification, those whose toxicity caused by previous anti-tumor treatment has not yet recovered to grade ≤1 (except for decreased lymphocyte count alone, alopecia, and the indicators mentioned in the inclusion criteria; According to the judgment of the researchers, after consultation with the sponsor, some tolerable chronic grade 2 toxicities may be excluded.
- •There are any factors that prevent the smooth progress of PET/CT examination or interfere with the interpretation of imaging results, including but not limited to the following situations: such as inability to lie flat, remain still or tolerate PET/CT scanning; It is known that there are metal implants or joint prostheses, etc.
- •It is known that there is an allergy or contraindication to any component of the test drug or its preparation.
- •Patients who had a second primary malignant tumor other than prostate cancer before enrollment, excluding malignant tumors with a low risk of metastasis and death that have been cured (5-year survival rate >90%), such as superficial squamous cell carcinoma of the skin, low-grade superficial bladder cancer, etc.
- •History of neurological or mental disorders, including epilepsy or dementia.
- •Participating in other clinical studies or having less than 4 weeks since the end of the last administration of the previous clinical study at the time of the first administration.
研究组 & 干预措施
HRS-1738 Group
Experimental
干预措施: HRS-1738 Injection (Drug)
结局指标
主要结局
Adverse events (AEs)
时间窗: About 1 year.
Serious adverse events (SAEs)
时间窗: About 1 year.
次要结局
- The maximum blood drug concentration (Cmax)(About 1 year.)
- Time to peak (Tmax)(About 1 year.)
- Biological half-life (t1/2)(About 1 year.)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Safety and Tolerability of SHR-1918 in Healthy SubjectsHyperlipemiaNCT05432544Beijing Suncadia Pharmaceuticals Co., Ltd72
Enrolling By Invitation
2 期
A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing CancersAdvanced Solid TumorsNCT05349409Suzhou Suncadia Biopharmaceuticals Co., Ltd.212
已完成
1 期
A Trial of SHR-1802 in Patients With Failure of Standard Treatment for Advanced Malignant TumoursMalignant TumoursNCT04414150Jiangsu HengRui Medicine Co., Ltd.28
已完成
1 期
HRS8179 在健康受试者中爬坡研究CTR2022016566
Unknown
1 期
SHR-1701 in Subjects With Metastatic or Locally Advanced Solid TumorsSolid TumorNCT03774979Jiangsu HengRui Medicine Co., Ltd.193